These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33939997)

  • 1. New Drugs Approved in 2020.
    Ebied AM; Elmariah H; Cooper-DeHoff RM
    Am J Med; 2021 Sep; 134(9):1096-1100. PubMed ID: 33939997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Drugs Approved in 2021.
    Ebied AM; Elmariah H; Cooper-DeHoff RM
    Am J Med; 2022 Jul; 135(7):836-839. PubMed ID: 35235820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Drugs Approved in 2022.
    Ebied AM; Elmariah H; Cooper-DeHoff RM
    Am J Med; 2023 Jun; 136(6):545-550. PubMed ID: 36889492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Drugs Approved in 2019.
    Ebied AM; Patel KH; Cooper-DeHoff RM
    Am J Med; 2020 Jun; 133(6):675-678. PubMed ID: 32145207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
    Monge AN; Sigelman DW; Temple RJ; Chahal HS
    JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Drug Approvals in 2018 - Another Record Year!
    Ebied AM; Na J; Cooper-DeHoff RM
    Am J Med; 2019 Sep; 132(9):1038-1043. PubMed ID: 30853471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priorities for the Priority Review Voucher.
    Ridley DB
    Am J Trop Med Hyg; 2017 Jan; 96(1):14-15. PubMed ID: 27573624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2017 Is Banner Year for Drug Approvals by the Food and Drug Administration.
    Ebied AM; Cooper-DeHoff RM
    Am J Med; 2018 Sep; 131(9):1025-1033. PubMed ID: 29626430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
    Mostaghim SR; Gagne JJ; Kesselheim AS
    BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases.
    Hwang TJ; Bourgeois FT; Franklin JM; Kesselheim AS
    Health Aff (Millwood); 2019 Feb; 38(2):313-319. PubMed ID: 30715972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do drug prices reflect development time and government investment?
    Keyhani S; Diener-West M; Powe N
    Med Care; 2005 Aug; 43(8):753-62. PubMed ID: 16034288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the FDA 2018 New Drug Approvals.
    Bedair A; Mansour FR
    Curr Drug Discov Technol; 2021; 18(2):293-306. PubMed ID: 31793428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.
    Chambers JD; Thorat T; Wilkinson CL; Neumann PJ
    Health Aff (Millwood); 2017 Aug; 36(8):1408-1415. PubMed ID: 28784733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.